UGT2B17

From Wikipedia, the free encyclopedia
Jump to: navigation, search
UGT2B17
Identifiers
Aliases UGT2B17, BMND12, UDPGT2B17, UDP glucuronosyltransferase family 2 member B17
External IDs MGI: 1919023 HomoloGene: 68144 GeneCards: UGT2B17
Gene location (Human)
Chromosome 4 (human)
Chr. Chromosome 4 (human)[1]
Chromosome 4 (human)
Genomic location for UGT2B17
Genomic location for UGT2B17
Band 4q13.2 Start 68,537,184 bp[1]
End 68,568,527 bp[1]
RNA expression pattern
PBB GE UGT2B17 207245 at fs.png
More reference expression data
Orthologs
Species Human Mouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001077

NM_152811

RefSeq (protein)

NP_001068

NP_690024

Location (UCSC) Chr 4: 68.54 – 68.57 Mb Chr 4: 86.92 – 86.93 Mb
PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

UDP-glucuronosyltransferase 2B17 is an enzyme that in humans is encoded by the UGT2B17 gene.[5][6]

UGT2B17 belongs to the family of UDP-glucuronosyltransferases (UGTs; EC 2.4.1.17), enzymes that catalyze the transfer of glucuronic acid from uridine diphosphoglucuronic acid to a variety of substrates, including steroid hormones.[supplied by OMIM][6]

References[edit]

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000197888 - Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000035836 - Ensembl, May 2017
  3. ^ "Human PubMed Reference:". 
  4. ^ "Mouse PubMed Reference:". 
  5. ^ Beaulieu M, Levesque E, Hum DW, Belanger A (Nov 1996). "Isolation and characterization of a novel cDNA encoding a human UDP-glucuronosyltransferase active on C19 steroids". J Biol Chem. 271 (37): 22855–62. PMID 8798464. doi:10.1074/jbc.271.37.22855. 
  6. ^ a b "Entrez Gene: UGT2B17 UDP glucuronosyltransferase 2 family, polypeptide B17". 

Further reading[edit]

  • Chung LW, Coffey DS (1978). "Androgen glucuronide. II. DIfferences in its formation by human normal and benign hyperplastic prostates.". Investigative urology. 15 (5): 385–8. PMID 76619. 
  • Moghissi E, Ablan F, Horton R (1984). "Origin of plasma androstanediol glucuronide in men.". J. Clin. Endocrinol. Metab. 59 (3): 417–21. PMID 6746859. doi:10.1210/jcem-59-3-417. 
  • Beaulieu M, Lévesque E, Tchernof A, et al. (1997). "Chromosomal localization, structure, and regulation of the UGT2B17 gene, encoding a C19 steroid metabolizing enzyme.". DNA Cell Biol. 16 (10): 1143–54. PMID 9364925. doi:10.1089/dna.1997.16.1143. 
  • Collier AC, Ganley NA, Tingle MD, et al. (2002). "UDP-glucuronosyltransferase activity, expression and cellular localization in human placenta at term.". Biochem. Pharmacol. 63 (3): 409–19. PMID 11853692. doi:10.1016/S0006-2952(01)00890-5. 
  • Chouinard S, Pelletier G, Bélanger A, Barbier O (2005). "Cellular specific expression of the androgen-conjugating enzymes UGT2B15 and UGT2B17 in the human prostate epithelium.". Endocr. Res. 30 (4): 717–25. PMID 15666817. doi:10.1081/ERC-200044014. 
  • Lazarus P, Zheng Y, Aaron Runkle E, et al. (2006). "Genotype-phenotype correlation between the polymorphic UGT2B17 gene deletion and NNAL glucuronidation activities in human liver microsomes.". Pharmacogenet. Genomics. 15 (11): 769–78. PMID 16220109. doi:10.1097/01.fpc.0000175596.52443.ef. 
  • Jakobsson J, Ekström L, Inotsume N, et al. (2006). "Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism.". J. Clin. Endocrinol. Metab. 91 (2): 687–93. PMID 16332934. doi:10.1210/jc.2005-1643. 
  • Park J, Chen L, Ratnashinge L, et al. (2006). "Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men.". Cancer Epidemiol. Biomarkers Prev. 15 (8): 1473–8. PMID 16896035. doi:10.1158/1055-9965.EPI-06-0141. 
  • Gallagher CJ, Muscat JE, Hicks AN, et al. (2007). "The UDP-glucuronosyltransferase 2B17 gene deletion polymorphism: sex-specific association with urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronidation phenotype and risk for lung cancer.". Cancer Epidemiol. Biomarkers Prev. 16 (4): 823–8. PMID 17416778. doi:10.1158/1055-9965.EPI-06-0823. 
  • Park JY, Tanner JP, Sellers TA, et al. (2007). "Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk.". Urology. 70 (2): 374–9. PMID 17826523. doi:10.1016/j.urology.2007.03.001. 
  • Chouinard S, Barbier O, Bélanger A (2008). "UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells.". J. Biol. Chem. 282 (46): 33466–74. PMID 17848572. doi:10.1074/jbc.M703370200.